ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 0622 • ACR Convergence 2021

    Ethnic Disparities in Giant-Cell Arteritis: A Clinical Comparison Among Caucasian and Hispanic Patients in the Inland Empire of Southern California

    Kathleena D'Anna and Mehrnaz Hojjati, Loma Linda University Health, Loma Linda, CA

    Background/Purpose: Giant-Cell Arteritis (GCA) is the most common systemic vasculitis among North Americans, historically described in Caucasian populations, with limited clinical data in other ethnic…
  • Abstract Number: 1410 • ACR Convergence 2021

    Predictors of Relapse in Giant-Cell Arteritis: A Retrospective Single Center Analysis

    Kathleena D'Anna1, David Lim2, Lorena Salto1 and Mehrnaz Hojjati1, 1Loma Linda University Health, Loma Linda, CA, 2Loma Linda University Health, Redlands, CA

    Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in North America, typically affecting Caucasian female adults over 50 years of age. Flares…
  • Abstract Number: 1874 • ACR Convergence 2021

    Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis

    Kaitlin Quinn1, Hugh Alessi2, Emily Rose3, Mark A. Ahlman4, Christopher Redmond4, Yiming Luo4, Ertugrul Cagri bolek5, Carol Langford6, Cristina Ponte7, Peter Merkel8 and Peter Grayson9, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2National Institutes of Health, Bethesda, Maryland, 3Case Western, Cleveland Heights, OH, 4National Institutes of Health, Bethesda, MD, 5Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, 6Cleveland Clinic, Moreland Hills, OH, 7Hospital de Santa Maria, Lisbon, Portugal, 8University of Pennsylvania, Philadelphia, PA, 9National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Disease activity assessment can be challenging in Takayasu’s arteritis (TAK), which can lead to difficulty in determining eligibility for enrollment into randomized clinical trials…
  • Abstract Number: 0952 • ACR Convergence 2021

    Outcomes of COVID-19 Infection in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica: Results from the COVID-19 Global Rheumatology Alliance Physician Registry

    Sebastian Sattui1, Richard Conway2, Michael Putman3, Andrea Seet4, Kaley Beins5, Catherine Hill6, David Liew7, Sarah Mackie8, Puja Mehta9, Lorna Neill10, Gimena Gomez11, Maria Salinas12, Federico Maldonado13, Henrique Moriz14, Samia Studart15, NAFICE ARAUJO16, Ann Knight17, Davide Rozza18, Luca Quartuccio19, Maxime Samson20, Stephane Bally21, Alexandre Maria22, Pascal Chazerain23, Rebecca Hasseli24, Ulf Müller-Ladner25, Bimba Franziska Hoyer26, Reinhard Voll27, Rita Pinheiro Torres28, Mariana Luis29, Sandra Lúcia Ribeiro30, Samar Al Emadi31, Jeffrey Sparks32, Tiffany Hsu33, Kristin D'Silva34, Naomi Patel34, Leanna Wise35, Emily Gilbert36, Maria Valenzuela-Almada37, Ali Duarte-Garcia38, Manuel Ugarte-Gil39, Emily Sirotich40, Jean Liew41, Jonathan Hausmann42, Paul Sufka43, Suleman Bhana44, Rebecca Grainger45, Wendy Costello46, Lindsay Jacobsohn47, Zara Izadi4, Anja Strangfeld48, Elsa Frazão Mateus49, Kimme Hyrich50, Laure Gossec51, Loreto Carmona52, Saskia Lawson-Tovey50, Lianne Kearsley-Fleet53, Martin Schaefer54, Milena Gianfrancesco4, Pedro Machado55, Zachary Wallace34, Jinoos Yazdany4 and Philip Robinson56, 1Hospital for Special Surgery, New York, NY, 2St. James's University Hospital, Dublin, Ireland, 3Medical College of Wisconsin, Brookfield, WI, 4University of California San Francisco, San Francisco, CA, 5Vasculitis Foundation, Kansas City, MO, 6Queen Elizabeth Hospital, Woodville, Australia, 7Austin Health, Heidelberg, Australia, 8School of Medicine, University of Leeds, Leeds, United Kingdom, 9University College London, London, United Kingdom, 10PMR GCA Scotland, Perth, United Kingdom, 11Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 12Hospital Privado Universitario de Córdoba, Cordoba, Argentina, 13Sanatorio Güemes, Buenos Aires, Argentina, 14Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, 15HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, 16Instituto de ASsistencia Medica ao Servidor Publico Estadual de São Paulo, São Paulo, Brazil, 17Rheumatology, Institute of Medical Sciences, Uppsala University, Uppsala, Sweden, 18Epidemiology Research Unit, Italian Society of Rheumatology, Rome, Italy, 19Clinical Rheumatology, Department of Medicine, University of Udine, Udine, Italy, 20CHU Dijon Bourgogne, Hpital Franois Mitterrand, Dijon, Dijon, France, 21Nephrology and Dialysis Service, Metropole Savoie Hospital Center, Chambery, France, 22Department of Internal Medicine and Multiorganic Diseases, Saint-Eloi University Hospital of Montpellier, Montpellier, France, 23Department of Rheumatology and Internal Medicine, Diaconesses Croix Saint Simon Hospital, Paris, France, 24Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany., Bad Nauheim, Germany, 25JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, 26Universittsklinikum Schleswig-Holstein, Kiel, Germany, 27Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 28Rheumatology Service, Egas Moniz Hospital, Lisboa Occidental Hospital Centre, Lisbon, Portugal, 29Department of Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portuga, Coimbra, Portugal, 30Universidade Federal do Amazonas, Amazonas, Brazil, 31Hamad medical corporation, Doha, Qatar, 32Brigham and Women's Hospital, Boston, MA, 33Brigham and Women's Hospital, Jamaica Plain, MA, 34Massachusetts General Hospital, Boston, MA, 35LAC+USC/Keck Medicine of USC, Pasadena, CA, 36Mayo Clinic, Jacksonville, FL, 37Division of Rheumatology, Mayo Clinic, Rochester, MN, 38Mayo Clinic, Rochester, MN, 39Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 40McMaster University, Hamilton, ON, Canada, 41Boston University, Boston, MA, 42Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, 43HealthPartners, Eagan, MN, 44Crystal Run Health, Montvale, NJ, 45University of Otago, Wellington, New Zealand, 46Irish Children's Arthritis Network, Bansha, Ireland, 47University of California San Francisco, Antioch, CA, 48Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 49Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 50University of Manchester, Manchester, United Kingdom, 51Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, 52Instituto de Salud Musculoesqueltica (InMusc), Madrid, Spain, 53Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 54German Rheumatism Research Center, Berlin, Germany, 55Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 56University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia

    Background/Purpose: Patients with primary systemic vasculitis (PSV) and polymyalgia rheumatica (PMR) may be at high risk for poor COVID-19 outcomes due to the treatments used,…
  • Abstract Number: 1412 • ACR Convergence 2021

    Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice

    Lara Sánchez-Bilbao1, Javier Loricera1, Juan Pablo Valdivieso Achá2, Clara Moriano3, Javier Narvaez4, Vicente Aldasoro5, Olga Maíz6, Rafael Melero7, Juan Ignacio Villa8, Paloma Vela9, Susana Romero-Yuste10, José Luis Callejas11, Eugenio De Miguel12, Eva Galindez-Agirregoikoa13, Francisca Sivera14, Jesús Carlos Fernández-López15, Carles Galisteo16, Iván Ferraz-Amaro17, Juan Carlos Nieto18, Juan Ramón de Dios19, Julio Sánchez20, Esther Fernández21, Isabel de la Morena22, Patricia Moya23, Roser Solans-Laqué24, Jose Luis Andreu25, Marcelino Revenga26, Valvanera Pinillos27, Andrea García-Valle28, Adela Gallego29, Carlota Iñíguez30, Cristina Hidalgo31, Noemí Garrido-Puñal32, Ruth López-González33, José Andrés Román-Ivorra34, Sara Manrique Arija35, Paz Collado36, Enrique Raya11, Francisco Navarro37, Antoni Juan Mas38, Carmen Ordas39, Maria Dolors Boquet40, Noelia Álvarez-Rivas41, Maria Luisa Velloso-Feijoo42, Cristina Campos-Fernández43, Íñigo Rúa-Figueroa44, Arantxa Conesa45, Eva Salgado46, Miguel Ángel gonzalez-Gay47 and Ricardo Blanco48, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario La Princesa, Madrid, Spain, 3Hospital Universitario de León, León, Spain, 4Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Complejo Hospitalario de Navarra, Pamplona, Spain, 6Hospital Universitario de Donostia, San Sebastián, Spain, 7Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 8Hospital Sierrallana, Torrelavega, Spain, 9Hospital General Universitario de Alicante, Alicante, Spain, 10Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 11Hospital San Cecilio, Granada, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Hospital Universitario de Basurto, Bilbao, Spain, 14Hospital Universitario de Elda, Alicante, Spain, 15Hospital Universitario Juan Canalejo, A Coruña, Spain, 16Hospital Universitari Parc Tauli, Saadell, Spain, 17Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 18Hospital General Universitario Gregorio Marañón, Madrid, Spain, 19Hospital Universitario de Araba, Mondragón, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 22Hospital Clínico Universitario de Valencia, Valencia, Spain, 23Hospital Sant Pau, Barcelona, Spain, 24Hospital Vall d'Hebron, Barcelona, Spain, 25Hospital Universitario Puerta de Hierro, Madrid, Spain, 26Hospital Ramón y Cajal, Madrid. Spain., Madrid, Spain, 27Hospital San Pedro, Logroño, Spain, 28Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, 29Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 30Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 31Hospital Universitario Salamanca, Salamanca, Spain, 32Hospital Universitario Virgen del Rocío, Sevilla, Spain, 33Complejo Hospitalario de Zamora, Zamora, Spain, 34Hospital Universitario y Politécnico La Fe, Valencia, Spain, 35Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, 36Hospital Universitario Severo Ochoa, Madrid, Spain, 37Hospital General Universitario de Elche, Elche, Spain, 38Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 39Hospital de Cabueñes, Gijón, Spain, 40Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, 41Hospital San Agustín, Aviles, Spain, 42Hospital Universitario de Valme, Sevilla, Spain, 43Consorci Hospital General Universitari de Valencia, Valencia, Spain, 44Hospital Universitario Doctor Negrín, Gran Canaria, Spain, 45Hospital Universitario de Castellón, Castellón, Spain, 46Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 47Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 48Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: One of the most feared complications of giant cell arteritis (GCA) is visual affection. Tocilizumab (TCZ) has demonstrated efficacy and safety in GCA. However,…
  • Abstract Number: 1876 • ACR Convergence 2021

    A Prospective Observational Cohort Study and Systematic Review of 40 Patients with Mouth and Genital Ulcers with Inflamed Cartilage (MAGIC) Syndrome

    Yiming Luo1, Ertugrul Bolek1, Kaitlin Quinn2, Kristina Wells3, Emily Rose4, Emily Rominger1, Levent Kilic5, Omer Karadag6, Cindy Clark1, Alicia Livinski1, Peter Grayson7 and Marcela Ferrada1, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4Case Western, Cleveland Heights, OH, 5Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 6Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, 7National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome is a rare and poorly understood entity with clinical features of both relapsing polychondritis (RP)…
  • Abstract Number: 1010 • ACR Convergence 2021

    Proton Pump Inhibitors Suppress IL-1 Mediated Carditis in a Murine Model of Kawasaki Disease

    Paul Tsoukas1, Melissa Kleinau2, Lysa Langevin2, Lily Morikawa3, Trang Duong1, Suzanne Tam4 and Rae Yeung5, 1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, ON, 4Hospital for Sick Children, Toronto, ON, 5The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Kawasaki disease (KD), is the leading cause of acquired heart disease in childhood. Up to 20% of patients may develop coronary artery lesions (CAL)…
  • Abstract Number: 1413 • ACR Convergence 2021

    Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis

    Mark Matza1, Adam Jarvie2, Ana Fernandes1, John Stone3 and Sebastian Unizony4, 1Massachusetts General Hospital, Boston, MA, 2Masssachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Winchester, MA

    Background/Purpose: Even with the use of tocilizumab (TCZ), significant glucocorticoid exposure (usually ³ 6 months) continues to be an important problem in giant cell arteritis…
  • Abstract Number: 1877 • ACR Convergence 2021

    Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics

    Yiming Luo1, Kaitlin Quinn2, Marcela Ferrada1, Elaine Novakovich1 and Peter Grayson3, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

    Background/Purpose: Takayasu’s arteritis (TAK) is an idiopathic inflammatory disease primarily affecting the aorta and its major branches. Mycobacterium tuberculosis is prevalent in developing countries and…
  • Abstract Number: 1047 • ACR Convergence 2021

    Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain

    ana Perez1, Arturo Rodriguez Pérez2, Pablo Fernandez-Navarro3, Fernando Albarran4, Cristina Bohorquez4, Atusa Movasat4, Lucia Ruiz4, Paula Pretel4, elena Rabadan4, Valentina Emperiale4, Adrian abbasi5, julio suarez5, Lorena Montano4, emilio rico5, alfredo prieto2, melchor Alvarez de Mon5 and beatriz perez3, 1Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, 2Faculty of Medicine. Alcala University, Alcala de Henares, Spain, 3Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain, 4Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, 5Hospital Universitario Príncipe de Asturias, Madrid, Spain

    Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…
  • Abstract Number: 1414 • ACR Convergence 2021

    The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States

    Mark Matza1, Karina Torralba2 and Minna Kohler3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Expedited referral systems or “fast-track” clinics incorporating vasculitis ultrasound (VUS) into the evaluation of patients with suspected giant cell arteritis (GCA) have shown reduced…
  • Abstract Number: 1880 • ACR Convergence 2021

    Description of an Internet-Based Cohort with a Self-Reported Diagnosis of Polyarteritis Nodosa

    Jason Springer1, Tanaz Kermani2, Dianne Shaw3, Kalen Young3, Cristina Burroughs4 and Peter Merkel5, 1Vanderbilt University Medical Center, Franklin, TN, 2University of California Los Angeles, West Hills, CA, 3Vasculitis Foundation, Kansas City, MO, 4Health Informatics Institute, Tampa, FL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Polyarteritis nodosa (PAN) is form of medium-vessel vasculitis with an estimated annual incidence of 1 per million. The rarity of the disease makes traditional…
  • Abstract Number: 0144 • ACR Convergence 2021

    Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada

    Cal Robinson1, Rahul Chanchlani2, Anastasia Gayowsky3, Elizabeth Darling2, Hsien Seow2 and Michelle Batthish2, 1The Hospital for Sick Children, Hamilton, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3ICES, Hamilton, ON, Canada

    Background/Purpose: The incidence of Kawasaki Disease (KD) has increased by nearly 50% in Ontario, Canada over the past two decades. Little is known about the…
  • Abstract Number: 1048 • ACR Convergence 2021

    Estimating the Weight of Rheumatologic Diseases in Mortality in Spain: Basic Cause of Death vs Multiple Cause Analysis

    ana Perez1, Fernando Albarran2, Cristina Bohorquez2, Atusa Movasat2, Lucia Ruiz2, Paula Pretel2, elena Rabadan2, Valentina Emperiale2, Adrian abbasi3, julio suarez3, lorena montano3, emilio rico3, alfredo prieto4, Inmaculada Leon5, melchor Alvarez de Mon3 and beatriz perez6, 1Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, 2Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, 3Hospital Universitario Príncipe de Asturias, Madrid, Spain, 4Faculty of Medicine. Alcala University, Alcala de Henares, Spain, 5Communicable Diseases. Instituto de Salud Carlos III, Madrid, Spain, 6Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain

    Background/Purpose: Classical statistics provide information on mortality rates for basic causes of death. Although many inflammatory rheumatic diseases decrease life expectancy, they are generally not…
  • Abstract Number: 1457 • ACR Convergence 2021

    Clinical Heterogeneity of the VEXAS Syndrome: A Case Series

    Matthew Koster1, Taxiarchis Kourelis1, Kaaren Reichard1, Tanaz Kermani2, David Beck3, Daniela Ospina Cardona4, Matthew Samec1, Abhishek Mangaonkar1, Kebede Begna1, Christopher Hook1, Jennifer Oliveira1, Samih Nasr1, Benedict Tiong5, Mrinal Patnaik1, Michelle Burke1, Clement Michet1 and Kenneth Warrington6, 1Mayo Clinic, Rochester, MN, 2University of California Los Angeles, West Hills, CA, 3National Institutes of Health, Bethesda, MD, 4National Institutes of Health, Germantown, MD, 5University of California Los Angeles Medical Center, Culver City, CA, 6Mayo Clinic, Rochester, Minnesota

    Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently described myeloid-driven autoinflammatory condition caused by somatic mutations affecting methionine-41 (p.Met41) in the…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology